Last reviewed · How we verify
MB-105
At a glance
| Generic name | MB-105 |
|---|---|
| Sponsor | March Biosciences Inc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-term Follow-up Study of Patients Who Received MB-105
- MB-105 in Patients With CD5 Positive T-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-105 CI brief — competitive landscape report
- MB-105 updates RSS · CI watch RSS
- March Biosciences Inc portfolio CI